Heavy Menstrual Bleeding Racial and Ethnic Disparities: What Every Woman Should Know

Why Race and Ethnicity Shape Heavy Menstrual Bleeding

Heavy menstrual bleeding affects roughly one in five women of reproductive age, but that burden is not shared equally. Epidemiological data from the CDC and multiple population-based studies consistently show that Black, Hispanic, American Indian, and Alaska Native women experience higher rates of the conditions that cause HMB, face longer diagnostic delays, and receive treatments that are more invasive and carry greater surgical risk.

The reasons are layered. They include biology, specifically the higher prevalence of uterine fibroids in Black women. They include socioeconomic access, particularly insurance gaps that limit office-based and minimally invasive procedures. They also include clinician bias: documented patterns where patient-reported bleeding severity is underestimated in women of color.

Understanding these patterns is not academic. It changes what questions you ask at your next appointment, what treatments you insist on discussing, and when to seek a second opinion.

Defining the Problem: What Counts as HMB

The ACOG Practice Bulletin on abnormal uterine bleeding defines HMB as bleeding that interferes with physical, emotional, social, or material quality of life. The 80 mL threshold is a research standard; clinically, if your period soaks through a pad or tampon in under an hour for several consecutive hours, that meets the threshold.

Racial disparities in HMB operate across every step of the care pathway: prevalence of underlying causes, time to diagnosis, type of treatment offered, and long-term outcomes including anemia.

Uterine Fibroids: The Sharpest Racial Divide

Uterine fibroids are the single most common structural cause of HMB. They are also the condition with the most clearly documented racial disparity in women's health.

Prevalence and Timing

By age 50, ultrasound-confirmed fibroid prevalence reaches approximately 80% in Black women and 70% in white women, but Black women develop fibroids earlier, on average a decade sooner, and their tumors are larger and more numerous at diagnosis. The NIEHS Uterine Fibroid Study, one of the most cited population-based investigations, found that Black women had a 2-3x higher age-adjusted fibroid incidence compared to white women after controlling for parity and BMI.

That earlier onset matters because it means more reproductive years lived with uncontrolled heavy bleeding, more cycles of iron-deficiency anemia, and more disrupted work and social functioning before a diagnosis is ever made.

Diagnosis Delay

A 2023 analysis published in the American Journal of Obstetrics and Gynecology found that Black women with symptomatic fibroids waited significantly longer from symptom onset to confirmed diagnosis than white women, a gap driven partly by lower rates of pelvic ultrasound ordering at initial visits and partly by clinician underestimation of reported symptoms. Research published in the journal Obstetrics and Gynecology has documented that Black women's pain and bleeding reports are systematically rated as less severe by providers, a finding consistent with broader literature on racial bias in pain assessment.

Treatment Disparity: Surgery Over Preservation

Once fibroids are diagnosed, the treatment offered to Black women skews heavily toward hysterectomy. A JAMA Network Open analysis of fibroid-related surgeries found that Black women were approximately 2.4 times more likely to undergo hysterectomy compared to white women, and less likely to be offered or receive myomectomy or uterine fibroid embolization, both of which preserve the uterus.

The WomanRx treatment-access framework below organizes the disparities by care stage, so you can identify exactly where a gap might be affecting your own care.

| Care Stage | Documented Disparity | Likely Driver | |---|---|---| | Symptom recognition | Black and Hispanic women more likely to normalize heavy bleeding | Cultural messaging, provider dismissal | | First clinical evaluation | Less likely to receive pelvic ultrasound at index visit | Implicit bias, triage protocols | | Diagnosis confirmation | Longer delay to fibroid or adenomyosis diagnosis | Referral gaps, imaging access | | First-line medical treatment | Less likely to be offered levonorgestrel IUD or tranexamic acid | Insurance, formulary restrictions | | Surgical referral | More likely to be referred for hysterectomy than UFE or myomectomy | Subspecialty access, surgeon volume | | Post-treatment anemia management | Less likely to receive IV iron pre-operatively | Resource allocation |

PCOS, Adenomyosis, and Other Causes of HMB Across Racial Groups

Fibroids dominate the disparity conversation, but they are not the only condition that produces HMB with unequal distribution.

PCOS and Hispanic Women

Polycystic ovary syndrome affects an estimated 8-13% of reproductive-age women globally, and Hispanic women carry a disproportionate burden of the metabolic features of PCOS including insulin resistance and anovulatory bleeding. Anovulatory cycles produce irregular, sometimes very heavy bleeding because without ovulation there is no progesterone to stabilize the endometrium. Hispanic women with PCOS are also less likely to be diagnosed early, partly because PCOS is often screened through irregular cycles rather than metabolic labs, and partly because access to reproductive endocrinology is lower in communities with fewer specialist resources.

Adenomyosis and the Data Gap

Adenomyosis, where endometrial tissue grows into the uterine muscle wall, causes heavy, painful periods and is increasingly recognized as underdiagnosed in all women. Definitive data on racial variation in adenomyosis prevalence is limited because the condition historically required hysterectomy for pathologic confirmation. As MRI diagnosis becomes more common, early reports suggest adenomyosis co-occurs with fibroids in Black women at high rates, potentially compounding HMB severity. This is an area where the evidence gap is real and where ACOG has called for more race-stratified research.

Coagulation Disorders

Von Willebrand disease is present in approximately 13% of women with HMB and is frequently missed, particularly in adolescents. There is no strong evidence that VWD prevalence differs by race, but access to hematology co-management is lower in under-resourced health systems, meaning women of color with HMB from a bleeding disorder may go years without the correct diagnosis.

Iron-Deficiency Anemia: The Compounding Consequence

Heavy blood loss each cycle leads directly to iron depletion. Among women with HMB, iron-deficiency anemia is the most common downstream complication, and it affects women of color at higher rates.

National Health and Nutrition Examination Survey data show that non-Hispanic Black women and Mexican American women have higher rates of iron-deficiency anemia than non-Hispanic white women across reproductive age groups. This is partly a consequence of higher HMB prevalence and partly reflects dietary access and socioeconomic factors that intersect with heavy bleeding.

The clinical significance is not trivial. Untreated iron-deficiency anemia causes fatigue, cognitive slowing, impaired exercise capacity, and in pregnancy, increased risk of preterm birth and low birth weight. Women who normalize exhaustion as part of their period experience may not recognize anemia as a condition requiring treatment.

A ferritin level below 30 ng/mL in a woman with heavy periods should prompt iron supplementation even if hemoglobin is still in the normal range. Women of color with HMB should specifically ask for ferritin, not just hemoglobin or a complete blood count, because hemoglobin can remain falsely normal in early iron depletion.

Socioeconomic and Structural Barriers to HMB Treatment

Even when controlling for age and comorbidities, insurance status and geographic access independently predict which treatments women receive.

Insurance and Procedure Access

The levonorgestrel intrauterine system (LNG-IUS, Mirena or Liletta) is the most effective non-surgical treatment for HMB, with a Cochrane review finding it superior to oral progestogens in reducing menstrual blood loss and improving quality of life. Its upfront cost, typically $500-$1,000 without insurance, is a barrier that affects lower-income women disproportionately.

Endometrial ablation, another highly effective uterine-sparing procedure, requires insurance pre-authorization in most plans and is frequently denied on first submission. Women without stable insurance, including many uninsured Hispanic and Indigenous women, may never have the procedure offered to them at all.

Tranexamic acid, an antifibrinolytic that reduces menstrual blood loss by approximately 40% in randomized trials, is generic and inexpensive. Yet research published in Obstetrics and Gynecology has shown it remains under-prescribed in primary care settings, where most lower-income women with HMB receive their gynecologic care.

Geographic Access to Subspecialty Care

Uterine fibroid embolization and hysteroscopic myomectomy require interventional radiology and advanced laparoscopic surgical skill respectively. These procedures are concentrated in academic medical centers and urban hospitals. Rural women, who are disproportionately American Indian and Alaska Native, often live more than 60 miles from the nearest facility offering UFE, effectively removing it from their treatment menu regardless of clinical eligibility.

HMB Across the Life Stages of Women of Color

Adolescence

Heavy periods beginning at menarche are common in adolescents of all races, but they are more likely to be dismissed as "normal" in girls of color. Adolescent HMB that soaks through protection hourly or causes school absence warrants investigation for coagulation disorders, PCOS-related anovulation, and in some cases early fibroids. The ACOG Committee Opinion on menstrual health in adolescents describes the menstrual cycle as a vital sign. If your daughter's periods are disabling, that deserves the same clinical attention as an abnormal blood pressure reading.

Reproductive Years and Fertility Considerations

For Black and Hispanic women in their 20s and 30s trying to conceive, fibroid-related HMB can directly impair fertility. Submucosal fibroids distort the uterine cavity and reduce implantation rates. ASRM guidance on uterine fibroids and reproduction states that myomectomy improves pregnancy outcomes when submucosal fibroids are present, yet access to high-volume myomectomy surgeons remains uneven by geography and insurance.

If you have HMB and want to preserve fertility, be explicit about that goal at every appointment. Treatment plans that include hysterectomy or ablation (which destroys the endometrial lining and precludes pregnancy) should never be presented as the only options before fertility-sparing alternatives have been fully discussed.

Perimenopause

The late reproductive years and early perimenopause, roughly ages 40-52, bring natural fluctuations in estrogen that can dramatically worsen fibroid-related and anovulatory HMB. Black women, who develop fibroids earlier and at higher density, often face the sharpest escalation of bleeding during this window. The Menopause Society's position statement on abnormal uterine bleeding in midlife recommends ruling out endometrial pathology before initiating hormonal management in women over 45 with new or worsening HMB.

Endometrial biopsy is a simple in-office procedure that takes under five minutes. If you are a woman of color over 40 with worsening periods and have not had one, ask for it directly.

Postmenopause

Postmenopausal bleeding is never normal and always requires evaluation. Women of color, particularly those with a history of unopposed estrogen exposure from anovulatory cycles or long-standing fibroids, may carry a modestly higher cumulative endometrial stimulation burden. Any bleeding after 12 consecutive period-free months needs pelvic ultrasound and likely endometrial biopsy, regardless of how light it seems.

What Clinician Bias Looks Like in Practice, and How to Respond

Implicit bias in pain and symptom assessment is one of the best-documented disparities in medicine. A 2016 study in PNAS found that a significant proportion of medical trainees held false beliefs about biological differences in pain sensitivity between Black and white patients, with those beliefs predicting undertreated pain.

In gynecology, the parallel finding is that Black women's bleeding descriptions are more likely to be classified as "subjective" or attributed to lifestyle before diagnostic imaging is ordered.

Here are specific strategies:

• Bring a menstrual diary or use a validated pictorial blood assessment chart (PBAC) to your appointment. Objective documentation reduces the room for subjective dismissal.
• State your impact plainly: "I missed two days of work last month because of my period" is harder to minimize than "my periods are heavy."
• Ask directly: "What is the next test or imaging study that would help explain why my bleeding is this heavy?"
• If an ultrasound is not offered at a first visit for HMB lasting more than six months, ask why and document that you asked.
• Request a referral to a gynecologist who specializes in minimally invasive surgery before accepting a hysterectomy recommendation.

The Evidence Gap: What We Do Not Yet Know

Honesty about the limits of existing data is not a weakness. It is what separates useful clinical writing from promotion.

Most randomized controlled trials of HMB treatments, including key trials of the LNG-IUS, tranexamic acid, and endometrial ablation, did not pre-specify or report outcomes stratified by race or ethnicity. The ECLIPSE trial comparing the LNG-IUS to usual medical treatment for HMB enrolled predominantly white British women. The ACCESS IUS trial, which evaluated LNG-IUD access in US safety-net settings, did include more racially diverse populations and found the device highly acceptable and effective across groups, but sample sizes were insufficient for formal subgroup analysis by race.

What this means practically: the efficacy data for current first-line treatments is almost certainly generalizable across race, since the mechanisms are biological. The access and utilization data tell a different story, and that is where the disparity is most actionable.

"We have good treatments for heavy menstrual bleeding," says Elena Vasquez, MD, WomanRx medical reviewer and board-certified OB-GYN. "What we do not have is equitable delivery of those treatments. A woman in a federally qualified health center deserves the same conversation about a levonorgestrel IUD or uterine fibroid embolization that a woman at an academic medical center gets. Closing that gap requires clinicians to proactively offer options, not wait for patients to ask for them."

When to Seek Care, and What to Ask For

HMB is not something to wait out. If your periods meet any of the following criteria, schedule an evaluation now:

• Soaking through a pad or tampon in under an hour for two or more consecutive hours
• Passing clots larger than a quarter
• Periods lasting longer than seven days
• Significant fatigue, shortness of breath, or brain fog around your period (possible anemia)
• Missing work, school, or social activities due to bleeding

At that evaluation, ask for:

1. A pelvic ultrasound (transvaginal if tolerated) to evaluate for fibroids, adenomyosis, and endometrial thickness
2. A complete blood count with ferritin to screen for iron-deficiency anemia
3. Von Willebrand factor antigen and activity if you have had heavy periods since adolescence or a personal or family history of bleeding problems
4. A full discussion of non-surgical options including the LNG-IUS, tranexamic acid, and combined hormonal contraception before any surgical referral is made

If you are told your bleeding is "normal" without imaging or labs, that is not a complete evaluation.